ARTICLE | Deals
Strong migraine launch allows Biohaven to pad pipeline with pair of deals
Revenues from Nurtec ODT sales and Pfizer deal position Biohaven to add SMA asset, anti-convulsive
February 25, 2022 11:26 PM UTC
With Biohaven’s cash position mounting from the strong launch of its migraine drug and its deal with Pfizer, the biotech is building its pipeline with a pair of new deals, landing a Phase III-ready asset for SMA and a platform to develop neurology therapies.
Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced the two deals concurrently with its 4Q21 and full-year earnings announcement, in which it said it had about $1 billion in liquidity at year-end...